Everads Announces First-in-Human Clinical Data for Suprachoroidal Injector
Everads Therapy has published favorable safety and performance data from its first-in-human trial of the Everads Injector for suprachoroidal drug delivery, demonstrating effective treatment for diabetic macular edema. The results were showcased in the journal Ophthalmology Science, highlighting the device’s safety, ease of use, and capability for targeted drug distribution. The company will also present three studies on its technology at the ARVO 2026 Annual Meeting.
– Publication reports favorable safety, tolerability, and device performance, while highlighting posteriorly directed drug distribution as visualized by thermal imaging – TEL AVIV, Israel, May 3, 2026 /PRNewswire/ — Everads Therapy, a clinical-stage company leveraging its novel…